Evidence map›Paper›PMID 30449808›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.

Takuya Sho, Goki Suda, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Takuya ShoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Goki SudaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Megumi KimuraDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Tomoe ShimazakiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Osamu MaeharaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Taku ShigesawaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Kazuharu SuzukiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Akihisa NakamuraDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Masatsugu OharaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Machiko UmemuraDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Takaaki IzumiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Naoki KawagishiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Masaru BabaDepartment of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Japan.
Masato NakaiDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Mitsuteru NatsuizakaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Kenichi MorikawaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Koji OgawaDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
NORTE Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV) infection is yet to be clarified. This is because no or only a few patients have been included in Japanese phase 3 trials. We herein report for the first time the successful treatment of glecaprevir and pibrentasvir in three Japanese patients with HIV and genotype 3 HCV coinfection as well as hemophilia. Glecaprevir and pibrentasvir treatment is safe and effective for Japanese patients with genotype 3 HCV and HIV coinfection.

Indexed as

HIV-1Aminoisobutyric AcidsAntiviral AgentsBenzimidazolesCoinfectionCyclopropanesDrug Therapy, CombinationGenotypeHepacivirusHepatitis C, ChronicHIV InfectionsHumansLactams, MacrocyclicLeucineMaleMiddle AgedAminoisobutyric AcidsAntiviral AgentsBenzimidazolesCyclopropanesglecaprevirLactams, MacrocyclicLeucinepibrentasvirProlinePyrrolidinesQuinoxalinesSulfonamidesgenotype 3glecaprevirHCVhemophiliaHIVpibrentasvir

Identifiers

PMID30449808
PMCPMC6465017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.